Clinical Research Directory

EMPagliflozin After Aortic Valve Replacement

Sponsor: Rigshospitalet, Denmark

Summary

The study is a randomized, placebo-controlled, and double-blinded trial in patients with aortic stenosis (AS) undergoing aortic valve replacement (AVR). After AVR, patients will be randomized 1:1 to empagliflozin (SGLT2i) or placebo to investigate whether empagliflozin is superior to placebo in reducing left ventricular mass and improve symptoms to 6 months.

Official title: EMPagliflozin After Aortic Valve Replacement - The EMPAVR Study - A Randomized Clinical Trial

Key Details

Conditions

Interventions

Locations (1)